Alexander Randolph Advisory Inc. Acquires New Holdings in Amgen Inc. (NASDAQ:AMGN)

Alexander Randolph Advisory Inc. purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 7,218 shares of the medical research company’s stock, valued at approximately $2,079,000. Amgen makes up approximately 1.9% of Alexander Randolph Advisory Inc.’s portfolio, making the stock its 21st biggest position.

A number of other large investors have also recently added to or reduced their stakes in the stock. BIP Wealth LLC lifted its stake in Amgen by 2.6% in the fourth quarter. BIP Wealth LLC now owns 1,249 shares of the medical research company’s stock valued at $360,000 after acquiring an additional 32 shares during the last quarter. Southland Equity Partners LLC grew its holdings in Amgen by 2.3% in the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock valued at $443,000 after buying an additional 34 shares in the last quarter. Acropolis Investment Management LLC raised its stake in Amgen by 3.5% in the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock worth $288,000 after purchasing an additional 34 shares in the last quarter. Opal Wealth Advisors LLC boosted its stake in shares of Amgen by 1.9% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after buying an additional 34 shares during the period. Finally, Marino Stram & Associates LLC lifted its position in shares of Amgen by 0.7% during the 4th quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock valued at $1,332,000 after acquiring an additional 34 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ AMGN traded up $0.60 during mid-day trading on Friday, reaching $269.98. 2,436,959 shares of the company’s stock were exchanged, compared to its average volume of 2,035,139. The firm has a market capitalization of $144.81 billion, a price-to-earnings ratio of 21.62, a price-to-earnings-growth ratio of 2.61 and a beta of 0.58. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The firm has a 50-day moving average price of $275.10 and a two-hundred day moving average price of $281.52.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. During the same period in the previous year, the business posted $4.09 EPS. The firm’s quarterly revenue was up 19.8% compared to the same quarter last year. Analysts predict that Amgen Inc. will post 19.43 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.33%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is currently 72.06%.

Analyst Ratings Changes

AMGN has been the subject of a number of research analyst reports. Oppenheimer restated an “outperform” rating and set a $350.00 price objective on shares of Amgen in a research report on Thursday, February 1st. SVB Leerink lowered Amgen from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $324.00 to $318.00 in a research report on Wednesday, February 7th. Raymond James initiated coverage on Amgen in a report on Thursday, March 28th. They issued a “market perform” rating on the stock. Morgan Stanley cut their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 7th. Finally, StockNews.com downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Ten investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $296.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.